Logo image of TTNP

TITAN PHARMACEUTICALS INC (TTNP) Stock Overview

NASDAQ:TTNP - US8883147055 - Common Stock

4.99 USD
+0.09 (+1.84%)
Last: 8/22/2025, 8:00:02 PM

TTNP Key Statistics, Chart & Performance

Key Statistics
52 Week High6.99
52 Week Low3.03
Market Cap6.64M
Shares1.33M
Float670.00K
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-5.23
PEN/A
Fwd PEN/A
Earnings (Next)01-01 2026-01-01
IPO01-18 1996-01-18
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


TTNP short term performance overview.The bars show the price performance of TTNP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

TTNP long term performance overview.The bars show the price performance of TTNP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of TTNP is 4.99 USD. In the past month the price increased by 22.6%. In the past year, price decreased by -18.6%.

TITAN PHARMACEUTICALS INC / TTNP Daily stock chart

TTNP Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 44.07 673.58B
JNJ JOHNSON & JOHNSON 17.93 431.79B
NVO NOVO-NORDISK A/S-SPONS ADR 14.69 253.19B
AZN ASTRAZENECA PLC-SPONS ADR 18.24 251.05B
NVS NOVARTIS AG-SPONSORED ADR 14.35 245.81B
MRK MERCK & CO. INC. 11.35 218.23B
PFE PFIZER INC 7.63 147.14B
SNY SANOFI-ADR 11.64 125.24B
BMY BRISTOL-MYERS SQUIBB CO 7.12 97.54B
GSK GSK PLC-SPON ADR 8.95 81.01B
ZTS ZOETIS INC 25.18 69.41B
TAK TAKEDA PHARMACEUTIC-SP ADR 53.52 49.02B

About TTNP

Company Profile

TTNP logo image Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. The company is headquartered in San Francisco, California. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.

Company Info

TITAN PHARMACEUTICALS INC

Suite 505, 400 Oyster Point Blvd

San Francisco CALIFORNIA 94080 US

CEO: Marc Rubin

Employees: 4

TTNP Company Website

TTNP Investor Relations

Phone: 14152444990

TITAN PHARMACEUTICALS INC / TTNP FAQ

What is the stock price of TITAN PHARMACEUTICALS INC today?

The current stock price of TTNP is 4.99 USD. The price increased by 1.84% in the last trading session.


What is the ticker symbol for TITAN PHARMACEUTICALS INC stock?

The exchange symbol of TITAN PHARMACEUTICALS INC is TTNP and it is listed on the Nasdaq exchange.


On which exchange is TTNP stock listed?

TTNP stock is listed on the Nasdaq exchange.


What is TITAN PHARMACEUTICALS INC worth?

TITAN PHARMACEUTICALS INC (TTNP) has a market capitalization of 6.64M USD. This makes TTNP a Nano Cap stock.


How many employees does TITAN PHARMACEUTICALS INC have?

TITAN PHARMACEUTICALS INC (TTNP) currently has 4 employees.


What are the support and resistance levels for TITAN PHARMACEUTICALS INC (TTNP) stock?

TITAN PHARMACEUTICALS INC (TTNP) has a support level at 4.88 and a resistance level at 5.1. Check the full technical report for a detailed analysis of TTNP support and resistance levels.


Should I buy TITAN PHARMACEUTICALS INC (TTNP) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TITAN PHARMACEUTICALS INC (TTNP) stock pay dividends?

TTNP does not pay a dividend.


When does TITAN PHARMACEUTICALS INC (TTNP) report earnings?

TITAN PHARMACEUTICALS INC (TTNP) will report earnings on 2026-01-01.


What is the Price/Earnings (PE) ratio of TITAN PHARMACEUTICALS INC (TTNP)?

TITAN PHARMACEUTICALS INC (TTNP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.23).


What is the Short Interest ratio of TITAN PHARMACEUTICALS INC (TTNP) stock?

The outstanding short interest for TITAN PHARMACEUTICALS INC (TTNP) is 5.19% of its float. Check the ownership tab for more information on the TTNP short interest.


TTNP Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to TTNP. When comparing the yearly performance of all stocks, TTNP is a bad performer in the overall market: 74.82% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

TTNP Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TTNP. While TTNP seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TTNP Financial Highlights

Over the last trailing twelve months TTNP reported a non-GAAP Earnings per Share(EPS) of -5.23. The EPS increased by 29.34% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -161%
ROE -192.87%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%66.89%
Sales Q2Q%N/A
EPS 1Y (TTM)29.34%
Revenue 1Y (TTM)-100%

TTNP Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

TTNP Ownership

Ownership
Inst Owners1.94%
Ins Owners29.69%
Short Float %5.19%
Short Ratio1.22